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Abstract
Background: NFkB signaling is critical for expression of genes involved in the vascular injury response. We have shown that
estrogen (17b-estradiol, E2) inhibits expression of these genes in an estrogen receptor (ER)-dependent manner in injured rat
carotid arteries and in tumor necrosis factor (TNF)-a treated rat aortic smooth muscle cells (RASMCs). This study tested
whether E2 inhibits NFkB signaling in RASMCs and defined the mechanisms.
Methodology/Principal Findings: TNF-a treated RASMCs demonstrated rapid degradation of IkBa (10–30 min), followed by
dramatic increases in IkBa mRNA and protein synthesis (40–60 min). E2 enhanced TNF-a induced IkBa synthesis without
affecting IkBa degradation. Chromatin immunoprecipitation (ChIP) assays revealed that E2 pretreatment both enhanced
TNF-a induced binding of NFkB p65 to the IkBa promoter and suppressed TNF-a induced binding of NFkB p65 to and
reduced the levels of acetylated histone 3 at promoters of monocyte chemotactic protein (MCP)-1 and cytokine-induced
neutrophil chemoattractant (CINC)-2b genes. ChIP analyses also demonstrated that ERb can be recruited to the promoters of
MCP-1 and CINC-2b during co-treatment with TNF-a and E2.
Conclusions: These data demonstrate that E2 inhibits inflammation in RASMCs by two distinct mechanisms: promoting new
synthesis of IkBa, thus accelerating a negative feedback loop in NFkB signaling, and directly inhibiting binding of NFkBt o
the promoters of inflammatory genes. This first demonstration of multifaceted modulation of NFkB signaling by E2 may
represent a novel mechanism by which E2 protects the vasculature against inflammatory injury.
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Introduction
Inflammation plays a major role in the pathogenesis of vascular
disease [1–7]. Medial smooth muscle cells (SMCs) are critical
target cells that are activated in the early phase of the vascular
injury response and signal to other cells, i.e. monocytes,
neutrophils, and adventitial fibroblasts, as well as to other SMCs,
in orchestrating subsequent vascular remodeling [8–12]. In vitro,
SMCs respond to pro-inflammatory stimuli, e.g. tumor necrosis
factor (TNF)-a with increased expression of chemokines, cytokines
and adhesion factors, thus promoting an inflammatory response.
In the setting of acute endoluminal injury, 17b-estradiol (E2)
inhibits inflammatory cytokine and chemokine expression, mono-
cyte and neutrophil infiltration and neointima formation in carotid
arteries of ovariectomized rats via an estrogen receptor (ER)
dependent mechanism [8–10,13–15]. Additionally, we have
shown that in vitro, E2 inhibits TNF-a induced inflammatory
mediator expression in isolated rat aortic (RA) SMCs in an ERb-
dependent manner [16].
In the setting of vascular injury, TNF-a activates NFkB,
a transcription factor that mediates the immediate-early in-
flammatory response [17–20]. Although numerous NFkB proteins
exist, the most common NFkB heterodimer contains p65 and p50.
Each of the NFkB proteins contains an N-terminal Rel homology
domain (RHD), which is important for DNA binding, dimeriza-
tion, inhibitor association and nuclear localization [21,22]. In most
cells, NFkB is bound to and inhibited by IkBa, which reduces the
ability of NFkB to bind DNA [23]. In response to TNF-a,
interleukin-1b (IL-1b), or other stimuli, the inhibitor of NFkB
kinase (IKK) complex is activated and phosphorylates IkBa, which
targets it for degradation by the proteasome. This effectively
liberates NFkB, which then translocates into the nucleus where it
binds to cognate DNA response elements found within the
promoters of target genes to induce their expression. NFkB
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e36890activation is critical for the expression of a variety of genes,
including IkBa and those involved in vascular inflammation, e.g.
cytokine-induced neutrophil chemoattractant (CINC)-2b and monocyte
chemotactic protein (MCP)-1 [24–26]. Previously, we have shown
that expression of MCP-1 and CINC-2b is inhibited by E2 in an
ER dependent manner in balloon injured carotid arteries of rats
and in RASMCs in vitro [9,16]. However, at present, it is not clear
exactly how E2 inhibits NFkB mediated expression of these genes
in SMCs. The current study tested directly the hypothesis that E2,
in an ER dependent manner, modulates the inflammatory
response to TNF-a stimulation in isolated RASMCs in vitro by
interfering with NFkB signaling and defined the precise sites of
molecular merging of E2 and NFkB signaling cascades that are
responsible for this effect.
Results
E2 does not Prevent IkBa Phosphorylation and
Degradation, but does Enhance IkBa mRNA and Protein
Levels in TNF-a treated RASMCs
Consistent with previous observations that IkBa processing is
a target for E2/ER signaling [27–29], we tested the hypothesis
that E2 inhibits cytokine-induced IkBa phosphorylation and
degradation in RASMCs, thus attenuating NFkB signaling.
Quiescent RASMCs were incubated with E2 or vehicle for
24 hrs, followed by TNF-a for 10, 20, 30, 40, 50 and 60 mins.
Total protein was extracted and the levels of total and phospho-
IkBa were assessed using Western blot analyses. RASMCs treated
with TNF-a for 10 min demonstrated increased levels of phospho-
IkBa, with rapid degradation of IkBa between 10–30 min
(Figure 1A), followed by a dramatic recovery at 60 min. Levels
of phospho-IkBa were not reduced by pretreatment with E2
(Figure 1). Although IkBa was degraded in the presence of E2 and
TNF-a between 10–30 min, the total levels of IkBa were elevated
compared to those in the presence of TNF-a alone between 30–
60 min (Figure 1A). These results were analyzed by densitometry
and are presented in Figure 1B. Because E2 does not prevent
TNF-a induced IkBa degradation, these data suggest that E2 may
attenuate NFkB signaling by inducing new IkBa mRNA synthesis.
To evaluate the effects of E2 on TNF-a induced IkBa mRNA
levels, RASMCs were treated as described above and IkBa levels
were analyzed using real-time RT-PCR analyses. The levels of
IkBa mRNA were increased by TNF-a stimulation between 30–
60 min (Figure 2), and were further enhanced by E2. These
findings suggest that E2 can reduce NFkB activity by increasing
the expression of IkBa mRNA and protein.
ERb Activation Enhances IkBa mRNA Expression and
Restoration of IkBa Protein in TNF-a treated RASMCs
We have previously shown that in vitro, E2 inhibits TNF-
a induced inflammatory mediator expression in RASMCs in an
ERb-dependent manner [16]. To test whether the effects of E2 on
TNF-a-induced IkBa expression are also mediated by ERb,
RASMCS were pretreated with the selective ERb agonist
diarylpropiolnitrile (DPN), the selective ERa antagonist methyl-
piperidinopyrazole (MPP) alone or in combination with E2, E2
alone or vehicle for 24 hrs, followed by TNF-a for an additional
45 or 60 min and subjected to Western blot analysis for IkBa
protein and real-time RT-PCR analysis for IkBa mRNA,
respectively. These time points were chosen because they capture
the recovery phase of IkBa resynthesis following TNF-a induced
phosphorylation and degradation (Figures 1 and 2).
At 45 min post TNF-a treatment, IkBa protein levels were
significantly lower in TNF-a treated RASMCs than in vehicle-
treated control cells (Figure 3A, lane 2), indicating that IkBa
protein expression had not completely recovered to vehicle control
levels (lane 1) at this time point Pretreatment with E2 or DPN for
24 hr significantly accelerated the recovery of IkBa protein levels
in TNF-a-treated cells (lanes 3, 4). In contrast, pretreatment with
the ER a agonist propylpyrazole triol (PPT) did not alter the
inhibitory effect of TNF-a on IkBa protein levels (Figure 3B, lane
4). In addition, the stimulatory effect of E2 on IkBa protein levels
in TNF-a-treated cells was abolished by pretreatment with
tetrahydrochrysene-R,R,-enantiomer (R,R-THC, an agonist on
ERa and an antagonist on ERb) 1 hr prior of E2 (Figure 3C, lane
6), but was not affected by pretreatment with the ERa antagonist
MPP (Figure 3A, lane 6), supporting the ERb dependency of the
effect. E2, DPN, MPP (Figure 3A, lanes 7, 8, 9), PPT (Figure 3B,
lane 2), or R,R-THC (Figure 3C, lane 2) alone had no effect on
IkBa protein levels in RASMCs. These results provide evidence
that the effect of E2 on TNF-a-regulated IkBa protein expression
is mediated by ERb, not ERa.
Quantitative real time RT-PCR analysis demonstrated that
IkBa mRNA levels were significantly increased in RASMCs at
60 min post TNF-a treatment (Figure 4, lane 2) compared to the
vehicle control. Pretreatment with E2 or DPN (lanes 3 and 4), but
not PPT (lane 5), further increased IkBa mRNA levels in TNF-a-
treated RASMCs. The stimulatory effect of E2 on IkBa mRNA
expression in TNF-a-treated cells was blocked by R,R-THC (lane
6), but not MPP (lane 7). E2, DPN, PPT, MPP or R,R-THC alone
(lanes 8–12) did not alter IkBa mRNA levels in RASMCs in the
absence of TNF-a treatment. Together, these findings suggest that
the E2 mediated enhancement of IkBa mRNA expression in
TNF-a treated RASMCs is mediated by ERb, not ERa.
E2, Through ERb, Recruits NFkB p65 to the IkBa Promoter
To understand the molecular mechanisms by which E2 might
enhance IkBa mRNA synthesis, Chromatin Immunoprecipitation
(ChIP) analyses were performed. Quiescent cells were pretreated
with E2, DPN or vehicle for 24 hrs and then treated with TNF-
a for 1 hr. In vehicle treated cells, ChIP assays revealed that NFkB
p65 was not detected at the IkBa promoter (Figure 5, lane 1).
Treatment with TNF-a, E2 or DPN alone (lanes 2, 3 and 5)
resulted in recruitment of p65 (4 to 9 fold) to the IkBa promoter
compared to vehicle control. When cells were pretreated with E2
or DPN and then challenged with TNF-a (lanes 4 and 6), the levels
of p65 at the IkBa promoter were not altered significantly in
response to additional TNF-a compared to the levels in the
presence of E2 or DPN alone. In addition, pretreatment with the
ERb antagonist R,R-THC blocked E2 induced recruitment of p65
to the IkBa promoter in TNF-a-treated cells (lane 8), indicating
ERb dependency of the effect.
ChIP analyses with anti-ERb antibody were performed to test
whether ERb was recruited to the IkBa promoter. In the vehicle
treated cells (Figure 5B, lane 1), ERb was detectable at the IkBa
promoter. TNF-a treatment did not alter the binding of ERb at
the IkBa promoter (lane 2). In the E2 alone or E2+TNF-a treated
cells, ERb level was increased 2-fold at the IkBa promoter (lanes 3
and 4). E2 induced-recruitment of ERb to the IkBa promoter was
abolished by pretreatment with the ERb antagonist R,R-THC
(lane 5). In contrast, ERa was not detected at the IkBa promoter
in response to E2 alone or coincides with the increased level of p65
at the IkBa promoter in the presence of E2 or E2+TNF-a (Data
not shown).
Histones are acetylated at promoters that are undergoing active
transcription [30]. The binding of acetylated histone at the
promoter of a gene indicates that the gene is actively transcribing.
ChIP assays determined that the levels of AcH4 at the IkBa
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compared to vehicle (Figure 5C, lanes 1 and 2). E2 alone had
no effect on binding of AcH4 to the IkBa promoter (lane 3). In the
presence of E2+TNF-a, the levels of AcH4 at the IkBa promoter
increased significantly (7-fold) compared to vehicle treatment (lane
4). The level of AcH4 at the IkBa promoter in the presence of
E2+TNF-a was higher (about 40%) than the level in the presence
of TNF-a alone, but the difference was not statistically significant.
In cells pretreated of R,R-THC prior to E2+TNF-a (lane 6), the
level of AcH4 at the IkBa promoter was not significantly different
from the levels in E2+TNF-a treated cells. Together, these data
suggest that treatment with E2, combined with TNF-a, signifi-
cantly enhanced the transcriptional activity of the IkBa gene
through an effect on ERb.
Figure 1. Representative Western blots of phospho-IkBa and IkBa in E26TNF-a treated RASMCs. Cells were pretreated with/without E2
(10
27 M) for 24 hrs then stimulated with TNF-a (1 ng/mL) for the times shown (A). Line graph shows the ratio of IkBa to b-actin in E26TNF-a treated
RASMCs (B). Results are mean6SE from 3 samples/group. #p,0.05 vs. TNF-a-treated RASMCs.
doi:10.1371/journal.pone.0036890.g001
Figure 2. IkBa mRNA expression measured by real-time RT-PCR and normalized using 18 S rRNA. Cells were pretreated with/without E2
(10
27 M) for 24 hrs then stimulated with TNF-a (1 ng/mL) for the times shown. Results are mean6SEM from 6 wells/group. *p,0.05 vs. Vehicle-
treated RASMCs; #p,0.05 vs. TNF-a-treated RASMCs.
doi:10.1371/journal.pone.0036890.g002
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MCP-1 and CINC-2b Promoters
ChIP assays determined that NFkB p65 was present at the
MCP-1 and CINC-2b promoters at low levels in the absence of
TNF-a or E2 (Figure 6A) and that these levels were not affected by
addition of E2 alone. At 1 hr post TNF-a treatment, the levels of
NFkB p65 at these promoters were increased (14- and 21-fold),
and these levels were reduced nearly to the control levels in the
presence of pretreatment with E2, suggesting that E2 inhibits the
ability of NFkB p65 to bind the promoters of these genes.
In the absence of TNF-a or E2 (Figure 6B), or in the presence of
E2 alone or TNF-a alone, ERb was barely detected at the MCP-1
or CINC-2b promoters. However, in the presence of E2+TNF-a,
ERb was detected at the MCP-1 and CINC-2b promoters. These
data suggest that in the presence of E2+TNF-a,E R b is recruited
to these promoters and that the presence of ERb coincides with
the reduced levels of NFkB p65.
ChIP assays determined that the MCP-1 and CINC-2b
promoters harbored moderate levels of AcH3 in the absence of
any stimuli (Figure 6C,), and that these levels were reduced in the
presence of E2 alone. TNF-a treatment increased the levels of
Figure 3. Role of ER isoforms on IkBa protein level. A. Pretreatment of ERb agonist DPN (10
27 M) or E2 enhanced IkBa protein level in response
to TNF-a treatment compared to TNF-a alone; ERa antagonist MMP (10
26 M) did not block the effect of E2 in TNF-a-treated cells. B. Pretreatment of
ERa agonist PPT (10
27 M) did not affect IkBa protein level in response to TNF-a treatment compared to TNF-a alone; C. ERb antagonist R,R- THC
(10
26 M) blocked the effect of E2 in TNF-a-treated cells. Cells were pretreated with E2, DPN, PPT or vehicle for 24 h, then treated with TNF-a (1 ng/ml)
for an additional 45 min. In some experiment groups, cells were pretreated with THC or MPP for 1 hr prior of E2. Bar graph shows the densitometric
analysis of relative IkBa expression normalized to to b-actin Level. Results are mean6SE from 6 samples/group. *p,0.05 vs. Vehicle-treated RASMCs;
#p,0.05 vs. TNF-a-treated RASMCs.
doi:10.1371/journal.pone.0036890.g003
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levels were diminished in the presence of E2, indicating that these
genes have reduced transcriptional activity in the presence of E2.
Together, these data indicate that these genes are inhibited by E2
in both basal and induced states. In the basal state, E2 reduces
levels of AcH3. In the induced (by TNF-a) state, E2 reduces the
levels of p65 and AcH3.
E2, Through ERb, Inhibits MCP-1 and CINC-2b mRNA
Expression in TNF-a treated RASMCs
To test whether E2 inhibits TNF-a-induced MCP-1 and CINC-
2b mRNA expression and to assess the ER subtype dependence of
the E2 effect, RASMCS were pretreated with E2, the selective
ERb agonist DPN, the selective ERa antagonist MPP alone or the
selective ERb antagonist R,R-THC alone in combination with E2,
or vehicle for 1 hr and subjected to real time RT-PCR analysis for
MCP-1 and CINC-2b mRNA, respectively. Quantitative real time
RT-PCR analysis showed that TNF-a stimulated expression of
MCP-1 and CINC-2b significantly compared to the vehicle
control (Figure 7). Pretreatment with E2 or DPN significantly
inhibited expression of MCP-1 and CINC-2b in cells treated with
TNF-a. In contrast, R,R-THC, but not MPP antagonized the
inhibitory effects of E2 on MCP-1 and CINC-2b mRNA
expression in TNF-a-treated cells. E2, DPN, MPP or R,R-THC
alone did not alter MCP-1 and CINC-2b mRNA in RASMCs in
the absence of TNF-a treatment. Together, findings suggest that
the E2 mediated anti-inflammatory effect in TNF-a treated
RASMCs is mediated by ERb, and not ERa.
Discussion
The multifaceted crosstalk between NFkB signaling and the
ERs has been well documented [31]. In numerous models, E2 and
ERs have been shown to increase levels of IkBa and reduce levels
of phosphorylated IkBa [28,32–34]. Moreover, both ERa and
ERb reportedly inhibit NFkB activity in an E2 dependent manner
in a variety of cell types [31,35–42], and molecular studies have
mapped the minimal domains of ERa necessary for these effects to
the ligand binding domain (LBD), hinge domain and DNA
binding domain (DBD) [43,44]. In vitro,E R a binds to NFkB p65,
p50 and c-Rel [43,45]; ERb inhibits the DNA binding ability of
NFkB p50, c-Rel and NFkB p65/p50 dimers [36,43,46], and both
ERs can prevent NFkB from binding to the IL-6 promoter
[43,46,47]. However, at present, there is a paucity of data to
clarify the role of E2 and/or ERs in regulating the activity of
NFkB in vascular cells.
Previously, we demonstrated that isolated RASMCs express
high levels of inflammatory mediators, including the neutrophil-
and monocyte-selective chemokines CINC-2b and MCP-1, when
stimulated by TNF-a and that E2 inhibits this process and reduces
the neutrophil chemotactic activity of media conditioned by TNF-
a treated RASMCs via an ERb-dependent mechanism [16].
Herein we extend our studies in order to elucidate the molecular
mechanisms by which E2 and ERb negatively regulate the NFkB
signaling pathway in RASMCs. Specifically, this study demon-
strates for the first time the multifaceted effects of E2 in negatively
modulating events in the NFkB pathway in a vascular cell type.
We show that E2 neither inhibits the production of TNF-a by
RASMCs (See Text S1 and Figure S1), nor blocks the nuclear
translocation of NFkB p65 (Figure S2). Further, we demonstrate
that both ERa and ERb proteins are expressed in our RASMCs in
an E2 and TNF-a independent manner (Figure S3). We
demonstrate that E2, via ERb, attenuates signaling through the
NFkB signaling pathway via a novel bimodal mechanism. First, E2
selectively enhance NFkB p65 binding to the IkBa promoter in
order to stimulate the expression of IkBa, a direct inhibitor of
NFkB activation. Second, E2 reduces the ability of NFkB p65 to
bind to the promoters of pro-inflammatory genes such as MCP-1
and CINC-2b, thereby inhibiting their transcriptional activity,
indicated by the binding of AcH3 to the promoters, and mRNA
expression. These findings support the intriguing hypothesis that
E2, via ERb, selectively modulates the nuclear activity of NFkB
p65 to ensure that NFkB signaling is dampened by heightened
IkBa levels, as well as by reducing the binding of nuclear NFkB
p65 to the promoters of genes that mediate the inflammatory
response.
IkBa is the one of the best documented inhibitors and
transcriptional targets of NFkB. Through its ability to interact
with NFkB proteins, IkBa masks the DBD of NFkB in order to
maintain NFkB inactive in the cytoplasm until such time that
Figure 4. IkBa mRNA expression measured by real-time RT-PCR and normalized using 18 S rRNA. Cells were pretreated with E2
(10
27 M), DPN (10
27 M), PPT (10
27 M) or vehicle for 24 hr, then treated with TNF-a (1 ng/ml) for an additional 1 hr. MPP (10
26 M) or THC (10
26 M)
was given to cells at 1 h before E2 treatment in some experiments. Results are mean6SEM from 6–9 wells/group. *p,0.05 vs. Vehicle-treated
RASMCs; #p,0.05 vs. TNF-a-treated RASMCs.
doi:10.1371/journal.pone.0036890.g004
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proteasomal-mediated degradation of IkBa,N F kB signaling is
ultimately terminated through NFkB mediated resynthesis of
IkBa, which re-establishes the inactive cytoplasmic pool of NFkB/
IkBa complexes [48,49]. Studies of the murine IkBa promoter
identified six NFkB and NFkB-like response elements that are
highly conserved in sequence, orientation and position within the
genomes of humans and pigs [48]. Although the IkBa promoter
appears to be devoid of NFkB proteins in the basal state, the IkBa
promoter is bound and activated by NFkB proteins within minutes
of NFkB activation [50,51].
Our studies demonstrate that neither DPN nor E2 when
administered alone stimulated IkBa mRNA expression in
RASMCs despite substantial recruitment of NFkB p65 at the
IkBa promoter. Furthermore, E2 alone -induced recruitment of
Figure 5. ChIP assays of the binding of NFkB p65 (A), ERb (B)
and AcH4 (C) to the IkBa promoter. Cells were pretreated with/
without E2 (10
27 M) or DPN (10
27 M) for 24 hrs and then stimulated
with TNF-a (1 ng/mL) for 1 hr. THC (10
26 M) was given to cells at 1 h
before E2 treatment in some experiments. ChIP samples were prepared
as described in the text and analyzed using antibodies specific for p65,
ERb or AcH4. The immunoprecipitated DNA fragments and input DNA
were analyzed by real-time PCR. The y axis shows values were
normalized to input DNA with values for vehicle treatment defined as
1. The numbers represent the mean6SEM from three experiments
repeated in duplicate. *p,0.05 vs. Vehicle-treated RASMCs; #p,0.05
vs. TNF-a-treated RASMCs.
doi:10.1371/journal.pone.0036890.g005
Figure 6. ChIP assays of binding of NFkB p65, ERb and AcH3 to
the MCP-1 and CINC-2b promoters. Cells were pretreated without or
with E2 for 24 hrs, then stimulated with TNF-a (1 ng/mL) for 1 hr. ChIP
samples were prepared as described in the text and analyzed using
antibodies specific for p65, ERb or AcH3. The immunoprecipitated DNA
fragments and input DNA were analyzed by by real-time PCR. The y axis
shows values were normalized to input DNA with values for vehicle
treatment defined as 1. The numbers represent result from three
experiments repeated in duplicate. *p,0.05 vs. Vehicle-treated
RASMCs; #p,0.05 vs. TNF-a-treated RASMCs.
doi:10.1371/journal.pone.0036890.g006
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IkBa promoter, indicating that the increased p65 binding was
insufficient to increase IkBa gene transcription. This finding
suggests that other unidentified cofactors are required for NFkB
p65-induced transcription of the IkBa gene under these
conditions. However, when cells were pretreated with E2 or
DPN and then challenged with TNF-a, both E2 and DPN
further enhanced the TNF-a-induced increases in IkBa mRNA
expression and protein levels, suggesting the possibility that TNF-
a may have recruited cofactors needed for IkBa gene transcrip-
tion. The binding of ERb, but not ERa at the IkBa promoter
was increased by E2 treatment. The ERb antagonist R,R-THC
Figure 7. E2 inhibited TNF-a-induced MCP-1 and CINC-2b mRNA expression in RASMCs through ERb. Cells were grown to subconfluence
(<95%) in 6-well plates, deprived of serum for 24 hrs, pretreated with E2 (10
27 M), DPN (10
27 M) or vehicle for 24 h, and then treated with TNF-
a (1 ng/ml) for an additional 1 hr. MPP (10
26 M), or R, R-THC (10
–6 M) was given to cells at 1h before E2 treatment in some experiments. Data,
expressed as means6SEM, are from real-time quantitative RT-PCR assays and are normalized by 18 S RNA. Data for MCP-1 and CINC-2b are
standardized to the mean mRNA level of the TNF-a-treated RASMCs. *p,0.05 vs. respective vehicle-treated RASMCs; #p,0.05 vs. respective TNF-a-
treated RASMCs.
doi:10.1371/journal.pone.0036890.g007
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tion (p65 and AcH4 binding) and expression (mRNA and
protein), suggesting that E2 may inhibit NFkB signaling by
specifically targeting and enhancing events at the IkBa promoter,
perhaps in a manner dependent on ERb. Curiously, using
a computer program that analyzes promoters for putative
transcription factor binding sites, we failed to identify any
potential ER binding elements (ERE) within the IkBa promoter.
These data suggest that ERb may not interact directly with the
IkBa promoter to promote the binding of NFkB p65 to the
promoter, but instead may work through recruitment of cofactors
that enhance both binding of NFkB p65 to the promoter and
transcription of the IkBa gene. Future studies will address how
ERb is required for E2 mediated NFkB recruitment to and
enhanced transcription of the IkBa gene.
In addition, we have observed that NFkB p65 is rapidly
recruited to the MCP-1 and CINC-2b promoters in the presence of
TNF-a. Under these conditions, ERb is absent from these
promoters, and transcriptional activity of these genes is signifi-
cantly increased compared to vehicle treatment, as indicated by
AcH3 binding on these promoters and mRNA expression of these
genes. In response to E2 pretreatment, binding of NFkB p65 to
these promoters is greatly reduced and binding of ERb is greatly
increased, transcriptional activity of these genes is significantly
reduced, as indicated by decreased binding of AcH3 on these
promoters and mRNA expression of these genes. At present, we
can not definitively state why binding of ERb and NFkB p65 at
the MCP-1 and CINC-2b promoters is mutually exclusive. Using
computer programs designed to identify putative ERE, we could
not identify any EREs within either the MCP-1 or CINC-2b
promoters. Thus, these findings suggest that the presence of ERb
at these promoters may occur through the use of an element that
remains to be identified, or that ERb interacts with these
promoters indirectly, i.e., through another DNA-binding protein
(cofactor). Our future studies are attempting to address this
question.
In summary, this study has elucidated a novel bimodal
mechanism by which E2 inhibits NFkB signaling and thereby
the inflammatory response to TNF-a in RASMCs. E2 both 1)
enhances expression of IkBa, a direct inhibitor of NFkB
activation, thus accelerating a negative feedback loop in NFkB
signaling, and 2) directly inhibits binding of NFkB p65 to the
promoters of inflammatory genes, including MCP-1 and CINC-2b,
thereby inhibiting their expression. The findings that, in the
presence of E2+TNF-a,E R b is recruited and the binding of NFkB
is reduced at the MCP-1 and CINC-2b promoters, suggest that the
ability of selective ERb activation to inhibit expression of
inflammatory mediators in activated RASMCs may be related,
in part, to interference with the DNA binding ability of NFkB p65
by ERb.
Methods
Cell Culture
Primary cultures of RASMCs were derived from 10-week-old
female Sprague-Dawley rats (Charles River), as previously
described [16,52]. All protocols were approved by the In-
stitutional Animal Care and Use Committee of the University of
Alabama at Birmingham and were consistent with the Public
Health Service Policy on Humane Care and Use of Laboratory
Animals (Office of Laboratory Animal Welfare, August 2002)
and the Guide for the Care and Use of Laboratory Animals
published by National Institutes of Health (NIH Publication
No. 96-01, revised in 2002). The animal protocol number is
100908574. Cells were cultured in complete medium containing
phenol red–free DMEM (Gibco) supplemented with 10% (vol/
vol) FBS, 4 mmol/L L-glutamine, 100 U/mL penicillin, and
100 mg/ml streptomycin. RASMCs were pre-treated with E2
(10
27 M) or vehicle (ethanol at a final concentration ,0.01%)
for 24 hrs in all experiments. Cells were used within 5 passages
and were identified as RASMCs by their characteristic
morphology and positive immunostaining for a-smooth muscle
actin (a-SMA, clone 1A4, DAKO). RASMCs pre-treated with or
without E2 for 24 hours were then incubated with TNF-a (1 ng/
mL) for various time periods from 10 min to 6 hrs. To assess the
ER dependence of the E2 effect on IkBa expression, cells were
pretreated with the selective ERb agonist DPN (10
–7 M) or the
selective ERa agonist PPT (10
–7 M) (Tocris Cookson, Ellisville,
MO) for 24 hrs and then incubated with 1 ng/ml TNF-a for an
additional 45 or 60 min. Another set of cells from the above
experiments were exposed to the selective ERa antagonist MPP
(10
26 M) or the selective ERb antagonist R,R-THC (10
26 M)
(Tocris Cookson, Ellisville, MO) for 1 hr before the E2 (10
–7 M)
pretreatment.
Real-time Quantitative RT-PCR Analyses
Real-time quantitative RT-PCR analysis was performed as
described before [9,10,16]. Total RNA was extracted from cells
using TRIzol (Invitrogen, Carlsbad, CA), and treated with
DNAase I to remove genomic DNA. The protein- and DNA-
free RNA was reverse transcribed to cDNA and analyzed using the
SYBR Green RT-PCR kit (Applied Biosystems, Foster City, CA)
and specific primers: IkBa forward, 59-CAGCAGACTCCACTC-
CACTT-39 and IkBa reverse, 59-GAGAGGGGTATTTCCTC-
GAA-39. MCP-1 forward 59-ATGCAGGTCTCTGTCACGCT -
39 and MCP-1 reverse, 59-GGTGCTGAAGTCCTTAGGGT-39;
CINC-2b forward 59- TCAGGGACTGTTGTGG -39 and CINC-
2b reverse, 59- TGACTTCTGTCTGGGTG-39. cDNA was
amplified by PCR in the iCycler for 40 cycles and relative RNA
levels were calculated using the iCycler software. Samples were
compared by the relative (comparative) Ct method. Fold induction
or repression was measured relative to controls and calculated
after adjusting for 18 s RNA (endogenous control) using 2
2DDCt,
where D Ct=Ct interested gene - Ct 18 s RNA and DDCt=DCt
treatment - DCt vehicle control.
Immunoblot Analyses
Quiescent RASMCs were incubated with E2 or vehicle for
24 hrs, followed by TNF-a for 10, 20, 30, 40, 50 and 60 min.
Total protein was extracted and total and phospho-IkBa levels
were assessed using Western blot analysis with selective anti-IkBa
(Santa Cruz) and anti-phospho-IkBa (Cell Signaling) antibodies.
Expression of ERa and ERb protein was assessed using Western
blot analysis with selective anti-ERa (Santa Cruz HC-20) and anti-
ERb (Millipore 07-359) antibodies. Protein loading was assessed
by stripping the membranes and reprobing with anti-b-actin
antibody (Sigma).
Chromatin Immunoprecipitation Assays
RASMCs were pretreated with E2 (10
27 M) or vehicle for
24 hrs and then treated with TNF-a (1 ng/mL) or vehicle for
1 hr. Cells were fixed with formaldehyde and subjected to
chromatin immunoprecipitation (ChIP) analyses as previously
described [53–55]. Briefly, cells were fixed with formaldehyde for
15 min and nuclei purified, then passed through a 22-gauge
needle three times and sonicated to an average size of 500–
1000 bps. Protein-DNA complexes were immunoprecipitated (IP)
using 5 mg of antibodies selective for NFkB p65 (Abcam), ERb
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immune complexes were adsorbed with protein A beads or
protein G beads blocked with bovine serum albumin and salmon
sperm DNA (Upstate Signaling Solutions). Immunoprecipitants
were washed, eluted and crosslinks were reversed overnight. The
next day, samples were digested with Proteinase K and clarified
by phenol:chloroform:isoamyl alcohol extraction. DNA was
purified using mini spin columns and IP and non-IP DNA
(Input) was analyzed by real time PCR using specific primers:
IkBa forward, 59 AAGTCGTCGGTGGGAAAC 39 and IkBa
reverse, 59 CCTGAGTGGCTGGAAAGT 39 that amplify 2405
to 2280 in the rat IkBa gene promoter; MCP-1 forward 59
GCACTTACTCAGCAGATTC 39 and reverse, 59
GCCTCAGCCTTTTATTGT 39 that amplify 2208 to 291
in the rat MCP-1 gene promoter; forward 59 CAAACGAG-
GACTGGGTAG 39 and reverse, 59 GACTTAGGTGCAGG-
GACT 39 that amplify 2346 to 2541 in the rat CINC-2b gene
promoter. Results are representative of three experiments.
Statistical Analysis
Data are expressed as mean6SEM. Statistical analysis was
performed with one-way ANOVA or Student’s t test, as
appropriate. Values of P,0.05 were considered significant.
Supporting Information
Figure S1 Co-treatment with E2 and TNF-a does not
stimulateTNF-aexpressioninRASMCs.Cellsweregrownto
subconfluence(<95%)in6-wellplates,deprivedofserumfor24 hrs,
pretreated with 10
27 M E2 or vehicle for 24 hrs, then treated with
TNF-a(1 ng/mL)fortheperiodsindicated.Conditionedmediawas
collected. Data, expressed as means6SEM, are from a double
sandwich ELISA assay.
(TIF)
Figure S2 Representative micrographs of RASMCs
pretreated with E2 (10
27 M) or vehicle for 24 hrs before
incubated with TNF-a (1 ng/mL) for 30 min. Cells were
analyzed using anti-NFkB p65 antibody (A1,B1,C1,D1) and nuclei
were stained with DAPI (A2,B2,C2,D2). Merged images are
shown in the panel A3,B3,C3,D3. E. Bar graph demonstrating the
percentage of cells with NFkB p65 nuclear translocation after
TNF-a6E2 treatment for 0, 15, 30 and 60 min. Results are
mean6SE from 3 slides/group; a total of .200 cells were
counted/group). *P,0.05 compared with vehicle control group.
(TIF)
Figure S3 Representative Western blots of ERa and ERb
in E26TNF-a treated RASMCs. Cells were pretreated with E2
(10
27 M) or vehicle for 24 h, and then treated with TNF-a (1 ng/
ml) for an additional 6 hrs. Blots was reprobed with antibody
against b-actin for input loading.
(TIF)
Text S1 Detailed protocol.
(DOC)
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